{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.10","upperLimit":"48.90","value":"10.30"},{"groupId":"OG001","lowerLimit":"4.35","upperLimit":"8.05","value":"6.30"},{"groupId":"OG002","lowerLimit":"9.10","upperLimit":"41.60","value":"20.00"},{"groupId":"OG003","lowerLimit":"19.90","upperLimit":"99.90","value":"62.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from first dose of study treatment to the first documentation of progressive disease (PD) or death from any cause during study\n\nPD:\n\n* Increase of 25% or more from nadir in serum M-protein, absolute increase of \\>= 0.5 g/dL.\n* Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \\>=200 mg/24 hours.\n* Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \\>=10%.\n* New bone lesions or soft tissue plasmacytomas or increase size of existing bone lesions or soft tissue plasmacytomas.\n* Hypercalcemia attributed to myeloma. Calculated using Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG001","title":"Phase 1b - ACY-1215 Dose Level 3"},{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG002","title":"Phase 2 - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG003","title":"Phase 2 - ACY-1215 Dose Level 3"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the Efficacy Evaluable population.","reportingStatus":"POSTED","timeFrame":"From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Weeks"}